Contact   |   Login
Human Pharmaceuticals Banner Image

Finished Pharmaceutical Products (FPPs)

Our consortium of companies has established a notable global presence in both patented and generic pharmaceuticals, and continues to enjoy a leadership position across both segments:

Patented: innovative and state-of-the-art

We have decades of expertise in formulating innovative dosage forms. Today we are leveraging on this expertise to go global by distributing our finished dosage products in various regulated markets across the globe. Specifically, HPD offers innovative products for the prevention, diagnosis and treatment of diseases, and covers several major therapeutic areas such as diabetes, cardiovascular diseases, oncology, and hemophilia to name a few†. The group thus plays an important part in improving the health of people around the globe.

Generics and Biosimilars: Low cost and high quality

Historically, generic medications were regarded to be substandard and low in efficacy due to their availability at low prices. But the fact that the company do not spend on marketing of these products is not known to many. Our group’s far-reaching level of operation and excellent know-how about the up-to-the-minute drug development enables us to produce most effective and superior dosage forms.

To respond to the needs of the greatest possible number of patients throughout the world, our group has intensified its strategy of diversification on the generics market. We produce wide range of generic medications for all age groups and various diseased conditions. Generic medications are not only cost effective and accurate in their actions but also save vital financial resources for medical treatments and its allied services. They prove to be one of the best in today’s world and their demands are rising drastically due to its aid in aging population and radical reduction in healthcare expenses. According to IMS Health, generic medicines saved the U.S. $1 trillion between 2002 and 2011. And our group of companies applies one global quality standard across our facilities and across our product lines, regardless of market.

We are on our way to intensify the generic market by diversifying its strategy, thereby making healthcare accessible for every individual worldwide.

Major Therapeutic Areas:

Featured Products:

CostLo™ OTC

CostLo™, a manufactured brand of Pharmapex, offers over 100 national brand equivalent formulas ... learn more

† Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specific countries. Some of the products may also be marketed under different trade names.

You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specific product in your country, you may simply contact us at

Quick Contact

Featured Products:

CostLo™ OTC

CostLo™, a manufactured brand of Pharmapex, offers over 100 national brand equivalent formulas ... learn more

Recent Newsletters:

Issue #: 211 – AHD:
by Animal Health Department

Issue #: 214 – CHD:
by Consumer Health Department

Issue #: 224 – F&F:
by Food & Feed Business Unit
Press Releases and Latest News:
PND releases a 200+ page catalog for 2016
Pharmapex's Nutrition Department releases an extensive 2016 catalog for dietary supplements.
Pharmapex's novel mastitis treatment offers hope to world farmers
Efficient feed-based mastitis treatment boosts livestock health with a unique microencapsulated technology.
FDA approves Farxiga to treat type 2 diabetes
The U.S. FDA today approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
© , Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved.